Tirzepatide vs. Semaglutide: Mechanism, Trial Data, and Tracking

The key difference in one sentence

Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). In clinical trials, tirzepatide produced greater average weight loss and glycemic control than semaglutide — but both are effective, and individual response varies.

Mechanism: what GLP-1 and GIP do

GLP-1 (glucagon-like peptide-1) is a gut-derived hormone released after eating. It stimulates insulin secretion, suppresses glucagon (which would otherwise raise blood sugar), slows gastric emptying, and reduces appetite through central nervous system signaling. GLP-1 receptor agonists mimic this effect at pharmacologic doses.

GIP (glucose-dependent insulinotropic polypeptide) is also a gut-derived hormone released after eating. It potentiates insulin release in a glucose-dependent manner and appears to enhance the effects of GLP-1 on fat tissue and energy expenditure — particularly in the context of obesity. Its role was historically underestimated because GIP alone does not produce meaningful weight loss. In combination with GLP-1 activation, it appears to amplify the effect.

Tirzepatide's dual agonism is why it is called a "twincretin" — it hits both incretin pathways simultaneously. This mechanism is why clinical trials showed larger effects.

Head-to-head clinical data

Direct comparison data comes primarily from the SURMOUNT program (tirzepatide) vs. STEP program (semaglutide 2.4 mg) and, more directly, from the SURPASS-2 trial which directly compared tirzepatide to semaglutide 1 mg in type 2 diabetes.

These are population averages from different trials, not a direct randomized comparison in a single study. Individual response varies significantly. Some people respond better to semaglutide; many respond better to tirzepatide; some don't respond meaningfully to either.

Side effect profiles

Both drugs share a similar side effect profile due to the shared GLP-1 mechanism:

• GI effects (nausea, vomiting, diarrhea, constipation) — most common, especially during dose escalation. Usually transient. Mitigated by slow escalation and dietary adjustments.
• Reduced appetite — an intended effect that can become excessive in some users (muscle loss risk from inadequate protein intake).
• Injection site reactions — both are subcutaneous injections. Site rotation reduces localized reactions.

Tirzepatide has a higher rate of GI side effects in some trial populations, thought to be related to the faster gastric-emptying changes from dual agonism. This is typically managed with the dose escalation schedule.

Dosing and half-life comparison

Both require weekly SubQ injection and dose escalation over weeks to months. The half-life chart at My Pep Calc shows accumulation and trough levels for both compounds on a weekly schedule — see the chart.

Tracking implications: why they're managed differently

Despite the similar once-weekly schedule, tirzepatide and semaglutide have different dose escalation ladders, different concentration units (tirzepatide doses are mg; semaglutide doses are typically mg but at much lower absolute numbers), and potentially different injection volume calculations depending on your pharmacy's formulation concentration.

If you switch from semaglutide to tirzepatide mid-protocol, your vial concentration, units to draw, and escalation calendar all change. My Pep Calc stores these per-compound so switching doesn't require recalculating everything from scratch — the old protocol stays in your log for comparison.

Our position on which is better

We don't have one. My Pep Calc is a neutral tracking tool. We track both. We don't recommend one over the other, and we don't have financial relationships with any pharmacy or prescriber who would benefit from steering you toward a specific formulation.

The question of which compound is right for your specific situation is one for your prescribing provider, with your labs, your goals, and your medical history in hand.